A phase II, open-label study of ONC201 in adults with recurrent high-grade glioma

Protocol: 
AAAS1885
Phase: 
II

A phase II, open-label study of ONC201 in adults with recurrent high-grade glioma

The purpose of this research study is to test how safe and how well an investigational
drug known as ONC201 works in treating high grade glioma (a type of brain cancer). The
FDA (the U.S. Food and Drug Administration) has not approved ONC201 as a treatment for
this condition.

Are you Eligible? (Inclusion Criteria)

1. Are you at least 18 years old?
2. Have you been diagnosed with a high-grade glioma?
3. Has your disease progressed?
4. Have you undergone previous treatment with radiotherapy?

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States